Search

Bevacizumab

vials formulated for intravenous oncology use. … [A192939,A192837,A192891,A193275] VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target.

Trastuzumab emtansine

Trastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic … disease or had their cancer recur within 6 months of adjuvant treatment.

Meropenem

In August 2017, a combination antibacterial therapy under the market name vabomere was approved for treatment of adult patients with complicated urinary tract infections (cUTI). … The treatment aims to resolve infection-related symptoms and achieve negative urine culture, where the infections are proven or strongly suspected to be caused by susceptible bacteria.

Insulin aspart

Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. … Insulin aspart is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.

Lonoctocog alfa

Cefepime

[A2457,A249050] Cefepime is normally used to treat severe nosocomial pneumonia and infections caused by multi-resistant microorganisms such as _Pseudomonas aeruginosa_, and is also indicated for the empirical

Bouteloua gracilis pollen

Bouteloua gracilis pollen is the pollen of the Bouteloua gracilis plant. Bouteloua gracilis pollen is mainly used in allergenic testing.

Parecoxib

A letter of non-approval for parecoxib was issued by the FDA in 2005. … It is approved through much of Europe for short term perioperative pain control much in the same way ketorolac (Toradol) is used in the United States.

Erenumab

Erenumab (AMG-334) (INN; trade name Aimovig) is a human monoclonal antibody designed specifically to bind and antagonize the calcitonin gene-related peptide receptor (CGRPR) as a means to prevent migraines. Aimovig, as released and marke...

Ustekinumab

In October 2019, it was also approved by the FDA for use to manage moderately to severely active ulcerative colitis in adults. … In September 2016, ustekinumab was additionally approved for the management of moderate to severe Crohn's disease in selected adult patients.